REFERENCES
- Craig JB, Powell BL. Review: The management of nausea and vomiting in clinical oncology. Am J Med Sci 1987; 293: 34–44.
- De Kemion JN, Murphy GP, Priore R. Comparison of flutamide and Emcyt in hormone-refractory metastatic prostatic cancer. Urology 1988: 312–317.
- Hedlund PO. Secondary treatment. Scand J Urol Nephrol 1991; (Suppl 139); 25: 53–5.2.
- Loening SA, Beckley S, Brady MF, et al. Comparison of estramustine phosphate, methotrexate and cisplatinum in patients with advanced hormone-refractory prostate cancer. J Urol 1983; 129: 1001–1006.
- Morrow GR. The assessment of nausea and vomiting. Cancer 1984; (Suppl): 53: 2267–2278.
- Murphy GP, Gibbons RP, Johnson DE, et al. A comparison of estramustine phosphate and streptozoto-cM in patients with advanced prostatic carcinoma who have had extensive irradiation. J Urol 1977; 118: 288–291.
- Giver IN, Simon RM, Aisner J. Antiemetic studies: a methodological discussion. Cancer Treat Rep 1986; 70: 555–563.
- Roila F, Tonato M, Cognetti F, et al. Prevention of cisplatin-induced emesis: a double-blind multicentre, randomised, crossover study comparing ondansetron and ondansetron plus dexamethasone. J Clin Oncol 1991; 9: 675–678.
- Smyth JF, Coleman RE, Nicholson M, et al. Does dexamethasone enhance control of acute cisplatin-induced emesis by ondansetron? Br Med J 1991; 303: 1423–1426.
- Smyth JF. The problems of emesis induced by cancer chemotherapy. Clinician 1988; 6: 2–12.
- Soloway MS, de Kemion JB, Gibbons RP, et al. Comparison of estramustine phosphate and vincristine alone or in combination for patients with advanced, hormone-refractory, previously irradiated carcinoma of the prostate. J Urol 1981; 125: 664–667.